Home › Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy
 

Keywords :   


Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy

2014-07-30 09:52:30| drugdiscoveryonline Home Page

Genocea Biosciences, Inc. a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, recently announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2)

Tags: trial phase dose optimization

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
20.09Construction giant collapses putting 2,400 jobs at risk
20.09KANSAI HELIOS Further Expands as System Supplier in Italy
More »